Latest "Zenobia Therapeutics" News Stories

08:51 EDT 23rd March 2018 | BioPortfolio

Here are the most relevant search results for "Zenobia Therapeutics" found in our extensive news archives from over 250 global news sources.

More Information about Zenobia Therapeutics on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Zenobia Therapeutics for you to read. Along with our medical data and news we also list Zenobia Therapeutics Clinical Trials, which are updated daily. BioPortfolio also has a large database of Zenobia Therapeutics Companies for you to search.

Showing "Zenobia Therapeutics" News Articles 1–25 of 6,200+


Global Veterinary Therapeutics Market to Mark CAGR of 6.0% Over Next 10 Years - announces publication of its recently generated research report titled, "GlobalVeterinary Therapeutics MarketBy Type (Therapeutics Drugs, Therapeutics Vaccines, Feed Additives Therapeutics), By Read more...

What You Need to Know About Indalo Therapeutics

Indalo Therapeutics is based in St. Louis and was formed in October 2016 from the merger of Antegrin Therapeutics and Cascadia Therapeutics.

Technical Perspectives on Argos Therapeutics, Omeros, Regulus Therapeutics, and Rhythm Pharma

Argos Therapeutics Durham, North Carolinaheadquartered Argos Therapeutics Inc.'s stock finished last Friday's session 3.20% higher at $0.15. A total volume of 1.81 million Read more...

Capricor Therapeutics to Present at the Piper Jaffray Healthcare Conference

About Capricor Therapeutics Capricor Therapeutics, Inc. (NASDAQ: CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics Read more...

Proteostasis Therapeutics Announces Withdrawal of Equity Offering Due to Market Conditions

About Proteostasis Therapeutics, Inc. Proteostasis Therapeutics, Inc. is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis (CF) and other diseases Read more...

Anika Therapeutics (ANIK) versus Onconova Therapeutics (ONTX) Financial Survey

Anika Therapeutics and Onconova Therapeutics are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership. Anika Therapeutics currently has a consensus target price of $62.50, indicating a potential upside of 16.84%.

What You Need to Know About DMD Therapeutics

DMD Therapeutics is based in Seattle, although at present it is a virtual company, and, as its name suggests, is focused on developing therapeutics for DMD.

Deals this week: Odonate Therapeutics, China Reform Holdings, Denali Therapeutics

US-based therapeutics developer Odonate Therapeutics LLC plans to raise $182.57m through an initial public offering (IPO) of 6,762,000 shares of...Read More... The post Deals this week: Odonate Therapeutics, China Reform Holdings, Denali Therapeutics appeared first on Drug Development Technology.

Breakfast Technical Briefing on Biotech Stocks -- Cytori Therapeutics, Sorrento Therapeutics, ... Cytori Therapeutics San Diego, Californiaheadquartered Cytori Therapeutics Inc.'s shares dropped 2.15%, closing Monday's trading session at $0.39. The stock recorded a trading Read more...

Summit Therapeutics plc: Summit Therapeutics to Participate in Upcoming Investor Conferences

Summit Therapeutics plc ('Summit', or the 'Company')SUMMIT THERAPEUTICS TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCESOxford, UK, 22 November 2017- Summit Therapeutics plc (NASDAQ: SMMT, AIM: SUM...

SMi Group announces the 9th Annual RNA Therapeutics Conference

21 - 22 February 2018, London, UK. As the requirement for targeted solutions for chronic diseases continues to grow, the interest of pharmaceutical and biotech companies has increasingly focused towards RNA therapeutics, such that by 2020, the RNA Therapeutics Market is predicted to attain $1.2 billion. One of the main challenges in RNA Therapeutics continues to be bridging the gap between in-vivo...

Realm Therapeutics to Present at the 2017 BIO Investor Forum

MALVERN, PA -- (Marketwired) -- 10/16/17 -- Realm Therapeutics PLC (AIM: RLM) (AIM: RLM) Realm Therapeutics plc ("Realm Therapeutics", "Realm" or the "Company") Realm Therapeutics to Present at th...

3 Biotech Stocks That Exploded in 2017

Biotech companies Nektar Therapeutics, Esperion Therapeutics, and Sangamo Therapeutics led the market this year.

UCB and Investor Syndicate Led by Novo Seeds Launch Syndesi Therapeutics to Develop Novel Therapeutics for Cognitive Disorders

LOUVAIN-LA-NEUVE, Belgium, February 8, 2018 /PRNewswire/ -- Syndesi Therapeutics to leverage UCB's expertise in neurology drug discovery to develop potential therapeutics in cognitive disorders wi...

Gain Therapeutics hopes 'pharmacological chaperones' can usher in new therapies for rare diseases

A new firm dubbed Gain Therapeutics has been spun out of Barcelona’s Minoryx Therapeutics, centered…

iCo Therapeutics Announces Ethics Approval for its Oral Amphotericin B Phase 1 Clinical Study

Vancouver, British Columbia--(Newsfile Corp. - November 22, 2017) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company"), and its recently formed subsidiary iCo Therapeutics Au...

Novartis, Pear Therapeutics to Develop Digital Therapeutics for Patients With Schizophrenia, MS

NewsNovartis has entered into a collaboration with Pear Therapeutics to develop novel prescription digital therapeutics, software applications designed to effectively treat disease and improve clinical outcomes for patients.

Juno Therapeutics Spinout Raises $90M

JW Therapeutics, a clinical stage biopharma company founded by Juno Therapeutics and WuXi AppTec Group, has closed a Series A financing worth $90 million.

Gilead’s Kite Teams Up with Sangamo Therapeutics for Cancer Therapeutics in a $3.1 Billion+ Deal

Kite, a Gilead Company, has inked a worldwide collaboration deal with Sangamo Therapeutics to develop oncology therapeutics.

PEAR raises $50m to develop digital therapeutics business

PEAR Therapeutics has raised $50m in a new financing round to fund development of its prescription digital therapeutics business. Prescription digital therapeutics are clinically-validated, FDA-cleared software applications that demonstrate safety...

Abeona Therapeutics Inc: Abeona Therapeutics gibt Finanzergebnisse und Geschäftserfolge des 4. Quartals 2017 bekannt

Telefonkonferenz für Anleger am Dienstag, 27. März um 10.00 Uhr ET NEW YORK und CLEVELAND (USA), 19. März 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), ein führendes, in der kli...

Spark Therapeutics, Inc.: Spark Therapeutics nimmt im März an mehreren Konferenzen teil

PHILADELPHIA, 23. Februar 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), ein voll integriertes Gentherapie-Unternehmen, das sich der Herausforderung in Bezug auf die Unvermeidbarkeit g...

Seattle Genetics Acquires Cascadian Therapeutics, Continuing a Strong ...

On January 31, two Seattle biotech companies, Seattle Genetics and Cascadian Therapeutics, announced a merger agreement under which Seattle Genetics will acquire Cascadian Therapeutics for $614 million. [1] The announcement catapulted Cascadian Therapeutics shares to a 16-month high, and a 69% increase over the previous day's closing price.

Spark Therapeutics, Inc.: Spark Therapeutics nimmt an mehreren Konferenzen im Februar teil

PHILADELPHIA, 2018-02-06 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), ein voll integriertes Gentherapie-Unternehmen, das sich der Herausforderung in Bezug auf die Unvermeidbarkeit genetis...

Abeona Therapeutics Inc: Abeona Therapeutics kündigt bevorstehende Präsentationen auf dem 14. jährlichen WORLDSymposium an

NEW YORK und CLEVELAND (USA), 3. Februar 2018 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (NASDAQ:ABEO), ein führendes, in der klinischen Erprobung tätiges Biopharmazieunternehmen, das sich auf d...

Quick Search


News Quicklinks